KIDS

Business Context and Reporting Period

Company: OrthoPediatrics Corp. (KIDS)

Filing Type: Form 10-Q (Unaudited)

Reporting Period: Three months ended March 31, 2026

OrthoPediatrics is a global medical device company focused exclusively on the pediatric orthopedic market, providing implants, instruments, and specialized braces for trauma, deformity correction, scoliosis, and sports medicine. The company operates over 50 orthotic and prosthetic (O&P) clinics in the U.S. and sells products in over 75 countries. The company continues to operate as a going concern despite an accumulated deficit of $285.9 million.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net revenue increased 13% ($7.0 million) year-over-year, driven by strong performance in Trauma and Deformity (+14%) and Scoliosis (+13%) categories. International revenue grew 22% to $14.1 million.
• Operating Expenses: Total operating expenses increased 5% to $51.7 million. Sales and marketing expenses rose 11% due to higher commissions and volume. General and administrative expenses increased 2% primarily due to personnel supporting clinic expansions and acquisitions.
• Other Income/Expense: Other expense increased significantly to $2.5 million (from $0.5 million income in Q1 2025), primarily due to a decrease in foreign exchange gains and higher interest expense ($2.1 million vs. $1.1 million).
• Acquisitions: The company completed the acquisition of London Orthotic Consultancy (LOC) in February 2026 and continued integration of O&P clinics acquired in 2025. Goodwill increased by $5.9 million during the quarter due to these acquisitions.
• Debt Structure: On March 31, 2026, the company amended its Term Loan Agreement to add a new $20 million delayed draw term loan facility, extending availability until June 30, 2027.

Guidance, Outlook, and Risks

• Liquidity: Management believes cash balances and expected cash flows are sufficient to fund operations for more than the next 12 months. However, the company anticipates continued losses in the near term as it invests in product portfolio expansion and consigned inventory.
• Seasonality: Revenue is typically higher in summer months and holiday periods due to increased pediatric surgeries during school breaks.
• Legal Proceedings: The company is involved in an arbitration with IMED Surgical regarding software ownership (the '377 Patent). On April 15, 2026, the arbitration tribunal dismissed the claims against OrthoPediatrics with prejudice. No other material legal proceedings are currently pending.
• Risk Factors: Key risks include the ability to achieve profitability, reliance on third-party manufacturers, regulatory compliance, and potential impairment of goodwill and intangible assets if future cash flows do not meet estimates.
• Stock Repurchase: A stock repurchase program of up to $5 million was approved in 2024, with an annual limit reduced to $250,000 after December 31, 2024. No shares have been repurchased to date.

Investor Verification Checklist

• Debt Covenants: Verify compliance with the Braidwell Term Loan covenants, specifically the requirement to maintain unrestricted cash equal to at least 25% of the outstanding principal amount.
• Acquisition Integration: Monitor the financial performance and integration of the recently acquired LOC and other O&P clinics to ensure they contribute to revenue growth as projected.
• Inventory Levels: Review the $134 million inventory balance, noting that approximately 60% is held on consignment, and assess the risk of obsolescence or write-downs.
• Convertible Notes: Track the $50 million convertible notes (4.75% interest, due 2030) and the conversion price of $40.98 per share to evaluate potential future dilution.
• Going Concern Status: While management asserts sufficiency of funds, monitor the trend of operating cash burn ($3.3 million in Q1) against the $50.9 million cash position to assess runway.